- Home
- ADUS vs SLNO Comparison
ADUS vs SLNO Comparison
Compare ADUS & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUS
- SLNO
- Stock Information
- Founded
- ADUS 1979
- SLNO 1999
- Country
- ADUS United States
- SLNO United States
- Employees
- ADUS N/A
- SLNO N/A
- Industry
- ADUS Medical/Nursing Services
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ADUS Health Care
- SLNO Health Care
- Exchange
- ADUS Nasdaq
- SLNO Nasdaq
- Market Cap
- ADUS 2.2B
- SLNO 1.9B
- IPO Year
- ADUS 2009
- SLNO 2014
- Fundamental
- Price
- ADUS $120.99
- SLNO $54.83
- Analyst Decision
- ADUS Buy
- SLNO Strong Buy
- Analyst Count
- ADUS 9
- SLNO 7
- Target Price
- ADUS $131.63
- SLNO $69.86
- AVG Volume (30 Days)
- ADUS 133.5K
- SLNO 505.3K
- Earning Date
- ADUS 11-04-2024
- SLNO 11-06-2024
- Dividend Yield
- ADUS N/A
- SLNO N/A
- EPS Growth
- ADUS 23.71
- SLNO N/A
- EPS
- ADUS 4.37
- SLNO N/A
- Revenue
- ADUS $1,133,806,000.00
- SLNO N/A
- Revenue This Year
- ADUS $9.57
- SLNO N/A
- Revenue Next Year
- ADUS $16.64
- SLNO N/A
- P/E Ratio
- ADUS $27.56
- SLNO N/A
- Revenue Growth
- ADUS 10.15
- SLNO N/A
- 52 Week Low
- ADUS $85.43
- SLNO $26.38
- 52 Week High
- ADUS $136.12
- SLNO $59.75
- Technical
- Relative Strength Index (RSI)
- ADUS 40.28
- SLNO 52.01
- Support Level
- ADUS $116.69
- SLNO $50.69
- Resistance Level
- ADUS $133.81
- SLNO $59.75
- Average True Range (ATR)
- ADUS 3.81
- SLNO 2.37
- MACD
- ADUS -0.74
- SLNO -0.60
- Stochastic Oscillator
- ADUS 25.12
- SLNO 45.68
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.